NASDAQ NMS - GLOBAL MARKET · LGVN
+2.63% · +$0.0218 · Vol 770.4K
Market closed · last close 4:00 PM ET · price as of 19:07:27 ET
Longeveron Inc

Longeveron Inc

Biotechnology
$0.8500
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
LGVN
Longeveron Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

65/ 100
Veridion Score
BUY BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is LGVN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading LGVN catalysts
About Longeveron Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
38
Country
US

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.8600
Day high
$0.8700
Day low
$0.8231
Previous close
$0.8282
52W high
$1.16
-26.72% from high
52W low
$0.4836
54% of range
Market cap
$26.9M
EPS
$-1.1100
Beta
1.18
Shares out
31.9M
Volume
770.4K
1.81× rel vol
Avg volume
424.8K
VWAP
$0.8485
Price history computed in-house
1W
+3.66%
1M
+41.67%
3M
+4.81%
1Y
+6.28%
YTD
+67.98%
SMA 50 $0.7091 · above
SMA 200 $0.7218 · above
52W position 54%

LGVN overview

Veridion Score
65
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around LGVN.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading LGVN Form 4 filings
Public disclosures

Congress activity in LGVN

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for LGVN in the cached public ledger.

Federal contracts

LGVN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for LGVN in this window.
Lobbying spend

LGVN lobbying filings, year to date.

Registered lobbying filings matched to Longeveron Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for LGVN in this window.
Loading news for LGVN
Analyst ratings
Sovereign unlock shows live analyst consensus for LGVN.
Options
Sovereign unlock shows live options positioning for LGVN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.